FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076366897> ?p ?o ?g. }

• W2076366897 endingPage "805" @default.
• W2076366897 startingPage "798" @default.
• W2076366897 abstract "To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC). A total of 283 chemotherapy-naïve patients with MCC were enrolled (FOLFIRI arm: n=146; FOLFOXIRI arm: n=137). In the FOLFOXIRI arm, CPT-11 (150 mg m−2) was given on d1, L-OHP (65 mg m−2) on d2, LV (200 mg m−2) on days 2 and 3 and 5-FU (400 mg m−2 as i.v. bolus and 600 mg m−2 as 22 h i.v. continuous infusion) on days 2 and 3. In the FOLFIRI arm, CPT-11 (180 mg m−2) was given on d1 whereas LV and 5-FU were administered in the same way as in the FOLFOXIRI regimen. Both regimens were administered every 2 weeks. There was no difference in terms of overall survival (median OS: 19.5 and 21.5 months, for FOLFIRI and FOLFOXIRI, respectively; P=0.337), median time to disease progression (FOLFIRI: 6.9 and FOLFOXIRI: 8.4 months; P=0.17), response rates (33.6 and 43% for FOLFIRI and FOLFOXIRI, respectively; P=0.168). Patients treated with FOLFOXIRI had a significantly higher incidence of alopecia (P=0.0001), diarrhoea (P=0.0001) and neurosensory toxicity (P=0.001) compared with patients treated with FOLFIRI. The present study failed to demonstrate any superiority of the FOLFOXIRI combination compared with the FOLFIRI regimen, although the observed median OS is one of the best ever reported in the literature." @default.
• W2076366897 created "2016-06-24" @default.
• W2076366897 creator A5002334565 @default.
• W2076366897 creator A5006180337 @default.
• W2076366897 creator A5010312876 @default.
• W2076366897 creator A5014224438 @default.
• W2076366897 creator A5026478600 @default.
• W2076366897 creator A5035832029 @default.
• W2076366897 creator A5038502241 @default.
• W2076366897 creator A5043849331 @default.
• W2076366897 creator A5045689517 @default.
• W2076366897 creator A5049509860 @default.
• W2076366897 creator A5054375277 @default.
• W2076366897 creator A5076032623 @default.
• W2076366897 creator A5078192662 @default.
• W2076366897 creator A5084377238 @default.
• W2076366897 date "2006-02-28" @default.
• W2076366897 modified "2023-10-10" @default.
• W2076366897 title "FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)" @default.
• W2076366897 cites W1549846058 @default.
• W2076366897 cites W1847455118 @default.
• W2076366897 cites W1897637667 @default.
• W2076366897 cites W1941365207 @default.
• W2076366897 cites W1979706544 @default.
• W2076366897 cites W1995684282 @default.
• W2076366897 cites W2000366267 @default.
• W2076366897 cites W2020830322 @default.
• W2076366897 cites W2032553799 @default.
• W2076366897 cites W2051318720 @default.
• W2076366897 cites W2059707463 @default.
• W2076366897 cites W2065982243 @default.
• W2076366897 cites W2118059295 @default.
• W2076366897 cites W2118971132 @default.
• W2076366897 cites W2121368761 @default.
• W2076366897 cites W2122731269 @default.
• W2076366897 cites W2128403792 @default.
• W2076366897 cites W2128447158 @default.
• W2076366897 cites W2133399075 @default.
• W2076366897 cites W2139248078 @default.
• W2076366897 cites W2146798192 @default.
• W2076366897 cites W2157416388 @default.
• W2076366897 cites W2165254830 @default.
• W2076366897 cites W2169946736 @default.
• W2076366897 cites W2272757036 @default.
• W2076366897 cites W2314927739 @default.
• W2076366897 cites W4293241248 @default.
• W2076366897 doi "https://doi.org/10.1038/sj.bjc.6603011" @default.
• W2076366897 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361370" @default.
• W2076366897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16508637" @default.
• W2076366897 hasPublicationYear "2006" @default.
• W2076366897 type Work @default.
• W2076366897 sameAs 2076366897 @default.
• W2076366897 citedByCount "339" @default.
• W2076366897 countsByYear W20763668972012 @default.
• W2076366897 countsByYear W20763668972013 @default.
• W2076366897 countsByYear W20763668972014 @default.
• W2076366897 countsByYear W20763668972015 @default.
• W2076366897 countsByYear W20763668972016 @default.
• W2076366897 countsByYear W20763668972017 @default.
• W2076366897 countsByYear W20763668972018 @default.
• W2076366897 countsByYear W20763668972019 @default.
• W2076366897 countsByYear W20763668972020 @default.
• W2076366897 countsByYear W20763668972021 @default.
• W2076366897 countsByYear W20763668972022 @default.
• W2076366897 countsByYear W20763668972023 @default.
• W2076366897 crossrefType "journal-article" @default.
• W2076366897 hasAuthorship W2076366897A5002334565 @default.
• W2076366897 hasAuthorship W2076366897A5006180337 @default.
• W2076366897 hasAuthorship W2076366897A5010312876 @default.
• W2076366897 hasAuthorship W2076366897A5014224438 @default.
• W2076366897 hasAuthorship W2076366897A5026478600 @default.
• W2076366897 hasAuthorship W2076366897A5035832029 @default.
• W2076366897 hasAuthorship W2076366897A5038502241 @default.
• W2076366897 hasAuthorship W2076366897A5043849331 @default.
• W2076366897 hasAuthorship W2076366897A5045689517 @default.
• W2076366897 hasAuthorship W2076366897A5049509860 @default.
• W2076366897 hasAuthorship W2076366897A5054375277 @default.
• W2076366897 hasAuthorship W2076366897A5076032623 @default.
• W2076366897 hasAuthorship W2076366897A5078192662 @default.
• W2076366897 hasAuthorship W2076366897A5084377238 @default.
• W2076366897 hasBestOaLocation W20763668971 @default.
• W2076366897 hasConcept C121608353 @default.
• W2076366897 hasConcept C126322002 @default.
• W2076366897 hasConcept C141071460 @default.
• W2076366897 hasConcept C2776694085 @default.
• W2076366897 hasConcept C2776705615 @default.
• W2076366897 hasConcept C2779804826 @default.
• W2076366897 hasConcept C2780259306 @default.
• W2076366897 hasConcept C2780456651 @default.
• W2076366897 hasConcept C2780962732 @default.
• W2076366897 hasConcept C526805850 @default.
• W2076366897 hasConcept C71924100 @default.
• W2076366897 hasConcept C90924648 @default.
• W2076366897 hasConceptScore W2076366897C121608353 @default.
• W2076366897 hasConceptScore W2076366897C126322002 @default.
• W2076366897 hasConceptScore W2076366897C141071460 @default.
• W2076366897 hasConceptScore W2076366897C2776694085 @default.
• W2076366897 hasConceptScore W2076366897C2776705615 @default.

• next